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A B S T R A C TObjectives: The phase 3 trial, Serine Protease Inhibitor Boceprevir and
PegIntron/Rebetol-2 (RESPOND-2), demonstrated that the addition of
boceprevir (BOC) to peginterferon-ribavirin (PR) resulted in signiﬁ-
cantly higher rates of sustained virologic response (SVR) in previously
treated patients with chronic hepatitis C virus (HCV) genotype-1
infection as compared with PR alone. We evaluated the cost-
effectiveness of treatment with BOC in previously treated patients
with chronic hepatitis C in the United States using treatment-related
data from RESPOND-2 and PROVIDE studies. Methods: We developed
a Markov cohort model to project the burden of HCV disease, lifetime
costs, and quality-adjusted life-years associated with PR and two
BOC-based therapies—response-guided therapy (BOC/RGT) and ﬁxed-
duration therapy for 48 weeks (BOC/PR48). We estimated treatment-
related inputs (efﬁcacy, adverse events, and discontinuations) from
clinical trials and obtained disease progression rates, costs, and
quality-of-life data from published studies. We estimated the incre-
mental cost-effectiveness ratio (ICER) for BOC-based regimens as
studied in RESPOND-2, as well as by patient’s prior response tosee front matter Copyright & 2013, International S
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h, PA 15261, USA.treatment and the IL-28B genotype. Results: BOC-based regimens
were projected to reduce the lifetime incidence of liver-related
complications by 43% to 53% in comparison with treatment with PR.
The ICER of BOC/RGT in comparison with that of PR was $30,200, and
the ICER of BOC/PR48 in comparison with that of BOC/RGT was
$91,500. At a willingness-to-pay threshold of $50,000, the probabilities
of BOC/RGT and BOC/PR48 being the preferred option were 0.74 and
0.25, respectively. Conclusions: In patients previously treated for
chronic HCV genotype-1 infection, BOC was projected to increase
quality-adjusted life-years and reduce the lifetime incidence of liver
complications. In addition, BOC-based therapies were projected to be
cost-effective in comparison with PR alone at commonly used
willingness-to-pay thresholds.
Keywords: hepatitis C, Markov model, protease inhibitor.
Copyright & 2013, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Chronic infection with hepatitis C virus (HCV) is a major public
health problem, with more than 170 million people infected
worldwide [1,2]. In the United States, chronic HCV infection is a
leading cause of chronic liver diseases and hepatocellular carci-
noma (HCC), and is the most common indication for liver trans-
plantation [1]. In 2007, there were 15,000 deaths related to HCV
infection in the United States, surpassing the nearly 13,000
deaths caused by HIV infection [3].Of the six HCV genotypes, genotype 1 is the most prevalent in
the United States and accounts for at least 70% of all chronic
infections, followed by genotypes 2 and 3 (14% and 8%, respec-
tively) [4]. HCV genotype 1 is also the most difﬁcult to treat with a
combination of peginterferon-ribavirin (PR)─less than 50% of
treated patients achieve a sustained virologic response (SVR),
which is the primary goal of the treatment. Response rates
are even lower in nonresponders (15.6%, conﬁdence interval
[CI] 12.4%–19.4%) to previous PR therapy who are re-treated with
PR [5].ociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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Table 1 – Baseline patient characteristics from
RESPOND-2.
Characteristics N ¼ 403
Sex, n (%)
Male 268 (67)
Female 135 (33)
Age (y)
Mean  SD 52.7  7.7
Range 26–74
Race, n (%)
Black 49 (12)
Non-Black 354 (88)
Prior treatment experience, n (%)*
Nonresponders 144 (36)
Relapsers 259 (64)
Baseline Metavir score, n (%)†
F0—no ﬁbrosis 18 (4)
F1—portal ﬁbrosis without septa 200 (50)
F2—portal ﬁbrosis with few septa 79 (20)
F3—numerous septa without cirrhosis 29 (7)
F4—cirrhosis 49 (12)
Missing‡ 28 (7)
HCV, hepatitis C virus; RESPOND-2, Serine Protease Inhibitor
Boceprevir and PegIntron/Rebetol-2.
* Prior nonresponders had a decrease in plasma HCV-RNA levels of
at least 2-log10 by week 12 of prior therapy but with detectable
HCV-RNA levels throughout the course of therapy. Prior relapsers
had undetectable HCV-RNA levels at end of prior therapy without
subsequent attainment of a sustained virologic response.
† A central pathologist determined the ﬁbrosis score. Twenty-eight
patients had missing data.
‡ Patients with missing Metavir score were not included in
V A L U E I N H E A L T H 1 6 ( 2 0 1 3 ) 9 7 3 – 9 8 6974The launch of two protease inhibitors (PIs)—boceprevir and
telaprevir—in 2011 represents a major advance in the treatment
of chronic HCV with signiﬁcant improvements in SVR rates [6–9].
The Serine Protease Inhibitor Boceprevir and PegIntron/Rebetol-2
(RESPOND-2) trial, an international, randomized, multicenter,
double-blind study, demonstrated that boceprevir, when added
to PR, leads to high SVR rates in patients with genotype 1 who
failed prior treatment with PR therapy [8]. The SVR rates were
signiﬁcantly higher in the two boceprevir-containing regimens
(59% and 66%) than in the control regimen of PR alone (21%, P o
0.001). RESPOND-2 did not include null responders. PROVIDE, a
single-arm trial, however, evaluated the effectiveness of boce-
previr in prior null responders and reported signiﬁcantly higher
SVR rates of 39% in comparison with a low historic rate of 16%
using PR [10]. Similarly, the pivotal trial of telaprevir, retreatment
of patients with telaprevir-based regimen to optimize outcomes
(REALIZE), evaluated the addition of telaprevir to PR in patients
with HCV genotype 1 infection who had no response or a partial
response to previous therapy or who had a relapse after an initial
response [7]. The SVR rates were signiﬁcantly higher (33%–83%)
with telaprevir-based regimens than in the control groups.
By substantially increasing the SVR rates, the use of PIs is
expected to inﬂuence the course of the disease by reducing the
incidence of liver-related complications and deaths. Because the
treatment cost of PI-based triple therapy is substantially higher
than that of PR therapy, it is not clear whether the PI-containing
regimens provide sufﬁcient value in patients who failed prior
treatment with PR. The main objective of our study was to
evaluate the cost-effectiveness of boceprevir-based regimens as
studied in RESPOND-2 and PROVIDE in comparison with PR alone
in previously treated patients with chronic HCV genotype 1
infection. In addition, we evaluated the cost-effectiveness of
telaprevir in previously treated patients by using data from
REALIZE.the model.Methods
We created a multicohort Markov model that simulated each
cohort through the trial design of RESPOND-2, and projected
health-related outcomes (costs and beneﬁts) beyond the time
period of the trial by using the natural history of progression of
HCV disease. Each cohort was determined by the following risk
factors or demographic characteristics: age (mean age), sex (male/
female), and baseline ﬁbrosis score (F0–F4). The patient character-
istics were based on patients enrolled in the RESPOND-2 trial
(Table 1). A total of 10 different patient proﬁles from RESPOND-2
deﬁned the cohorts explored in our model.Treatment Regimens Based on RESPOND-2 Study Design
The trial randomized 403 patients in a 1:2:2 ratio to one of three
treatment groups (Fig. 1). The ﬁrst group received PR for 48 weeks
(abbreviated as PR48). The second group received response-
guided-therapy (RGT), starting with 4 weeks of PR followed by
boceprevir plus PR for 32 weeks (abbreviated as BOC/RGT). Those
with undetectable HCV-RNA levels at weeks 8 and 12 completed
therapy at week 36, whereas those with detectable HCV-RNA
levels at week 8 (but undetectable at week 12) received PR for an
additional 12 weeks. The third group received PR for 4 weeks
followed by boceprevir plus PR for 44 weeks (abbreviated as BOC/
PR48). In all three groups, patients who failed to achieve unde-
tectable HCV-RNA levels at week 12 discontinued therapy and
entered follow-up, regardless of their previous HCV-RNA level
measurements. At the end of the treatment, patients were
followed up to week 72.Model Structure
We divided the model into two parts: the ﬁrst part simulated the
treatment strategies, and the second part modeled the natural
history of the hepatitis C disease (Fig. 2). The treatment and
follow-up period were modeled by using a weekly cycle to allow
for early discontinuations, whereas the natural-history part used
a cycle length of 1 year.
During the treatment phase, patients entered the model with
chronic HCV disease and began antiviral drug therapy. At each
cycle, a patient could discontinue treatment for medical or
nonmedical reasons, fail to pass a futility rule, or continue
treatment. Patients could develop anemia during treatment,
which was managed by erythropoietin (EPO) or ribavirin dose
reduction. At the end of treatment, patients who failed to pass a
futility rule or had detectable HCV-RNA levels were considered
treatment failures and returned to chronic HCV health states.
Patients who had undetectable HCV-RNA levels at the end of
treatment (i.e., end-of-treatment response ) were followed for 24
weeks. After 24 weeks, if the patient still had undetectable HCV-
RNA levels, the patient had achieved SVR; otherwise, he or she
was considered to be a treatment relapse.
The second component of the model simulated the natural
history of chronic HCV disease. The model was designed to be
consistent with the current understanding of the biology of
chronic HCV-related liver disease and its treatment and is similar
to other published health economic models of HCV disease [11–14].
Our state-transition model consists of 14 health states (Fig. 2).
States capturing the severity of chronic HCV infection are
described by the degree of ﬁbrosis by using the Metavir scoring
system: no ﬁbrosis (F0), portal ﬁbrosis without septa (F1), portal
PR + Placebo 
Discontinue treatment and enter natural history phase of the model 
PR 
Detectable HCV RNA at TW12 
Undetectable HCV RNA at TW12 
PR48: 
PR + B 
Discontinue treatment and enter natural history phase of the model 
PR + B 
PR 
Follow-up 
Detectable HCV RNA at TW12 
Undetectable HCV RNA at TW12 
BOC/PR48: 
0 4 12 36 48 72 
Week: 
PR + B PR BOC/RGT: 
Discontinue treatment and enter natural history phase of the model 
Detectable HCV RNA at TW12 
Detectable HCV RNA at TW 8 but Undetectable at TW12 
PR + B 
Undetectable HCV RNA at TW 8 and TW12 
PR + B 
PR + B 
Follow-up 
Follow-up 
PR + Placebo Follow-up 
Fig. 1 – Strategies based on the RESPOND-2 trial for treatment-experienced patients. BOC/PR48, peginterferon–ribavirin-
boceprevir regimen; BOC/RGT, response-guided therapy; HCV, hepatitis C virus; PR48, peginterferon-ribavirin regimen;
RESPOND-2, Serine Protease Inhibitor Boceprevir and PegIntron/Rebetol-2; TW, treatment week.
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and cirrhosis (F4). In addition, the model includes states that
deﬁne advanced liver diseases, liver transplant (LT), SVR (cir-
rhotic and noncirrhotic at baseline), and death. The model
was developed by using Microsoft Excel (Microsoft Corp.,
Redmond, WA).
The progressive disease model assumed that a person with a
given ﬁbrosis score may progress to more severe stages of liver
disease or may remain in that health state. In the absence of
successful treatment, regression to less severe health states was
not permitted. After a successful treatment, however, a person
can achieve SVR, which was considered a cure for HCV in
patients without cirrhosis. We assumed that a cured person
who started treatment in health states F0 to F3 would not become
symptomatic again. However, patients with cirrhosis continued
to face some risk of liver disease (decompensated cirrhosis [DC]
and HCC) even if they achieved SVR [15]. For this purpose, we
stratiﬁed the SVR state by patient’s baseline ﬁbrosis stage before
treatment (“SVR, F0–F3” and “SVR, F4”).
Patients who return to chronic HCV health states can develop
serious liver disease. Patients with compensated cirrhosis are at
risk for developing DC and HCC. Although there are different
modes of decompensation (i.e., ascites, variceal hemorrhage, and
encephalopathy), we modeled them as one health state instead
of different health states because these decompensation modes
are not mutually exclusive. If a patient developed DC and/or HCC,
then the patient could receive an LT. To account for different
mortality rates of DC during the ﬁrst year and subsequent years,
the DC state was divided into two states: ﬁrst year (DC1) andsubsequent years (DCþ). Similarly, the LT health state was
divided into two—“Liver Transplant” and “Post-Liver Transplant.”
Patient in DC, HCC, and LT were subjected to excess mortality
compared with the general population, whereas all other patients
faced the same mortality risk as the general population.
Assumptions
We assumed that there is no progression of disease while patients
are on treatment. This assumption will have only a minimal or no
impact on results because HCV is a slow progressing disease that
can take 20 to 30 years to reach cirrhosis from the no-ﬁbrosis state
whereas the treatment period lasts at most 48 weeks. In addition,
only a fraction of patients in whom treatment will eventually fail
continue beyond week 12. We did not model the possibility of
remission from health states F0 and F1 because the likelihood of a
chronically infected person spontaneously clearing HCV is very
small [14]. As was done in many previous models, we assumed
that all patients continue to progress when not treated. Some
studies, however, suggest that a proportion of patients in the F0
state will not progress even if untreated [11,13]. This assumption
biases the base-case analysis in favor of the use of triple therapy.
The importance of this assumption was tested in the sensitivity
analysis. Patients who received an LT were not explicitly modeled
for the risk of reactivation and progression to liver disease. The
post-LT state indirectly took into account the mortality, however,
quality of life, and cost of reinfection after the LT. We also
assumed no long-term beneﬁts of treatment for patients who
relapsed or did not respond. This assumption leads to the
HCC
Lv-Death
DC*
F0 F3F2F1 F4
LT
PLT
Tx
Failure?
Discontinue
Tx?
Attain
ETR?
Attain
SVR
N
Y
Y
N
Y
N
N
SVR, F0-F3
Begin
Tx
Y
SVR, F4
Fig. 2 – State-transition diagram for chronic hepatitis C and liver disease model. The model consists of two components:
treatment and natural history. If patients discontinue treatment (Tx), or fail to achieve an end-of-treatment response (ETR) or a
sustained virologic response (SVR), they enter the natural history component of the model, which consists of 14 health states.
These include ﬁbrosis states (F0–F4); decompensated cirrhosis (ﬁrst year [DC1] and subsequent years [DCþ]); hepatocellular
carcinoma (HCC); liver transplant (ﬁrst year [LT] and subsequent years [PLT]; liver-related death (Lv-Death); death from all
other causes (not shown here); and SVR status states stratiﬁed by ﬁbrosis stage (“SVR, F0–F3” and “SVR, F4”). N, no; Y, yes.
*For clarity, two decompensated states—DC1 and DCþ—are shown as one state, that is, DC.
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Because the proportion of patients who relapsed or did not
respond was higher with dual therapy, this assumption also biases
the analysis against the use of dual therapy. Our model included
only the currently approved and available treatments, and did not
include any treatment that would be available in the future.Treatment-related inputs
We used RESPOND-2 data to estimate all treatment-related input
parameters (Table 2). Speciﬁcally, we estimated efﬁcacy rates,
treatment-failure rates, probability and duration of anemia, and
duration of EPO use for the management of anemia associated
with each treatment strategy.Epidemiological Inputs
The model required epidemiological inputs that describe the rate
of HCV progression, the probability of receiving an LT, and both
all-cause and liver-related mortality rates (Table 3). The progres-
sion rates determined the amount of time patients spent in each
health state, the likelihood of developing serious complications
associated with liver disease, and the probability of requiring
an LT.We used the progression rates of ﬁbrosis stages from Thein
et al. [16], a recent study that provides a systematic review and
meta-analysis of published progression rates from 111 studies of
individuals with chronic HCV infection. They provided stage-
speciﬁc progression rates by ﬁbrosis level. These estimates also
adjust for biases attributable to study design and selection factors
associated with the study population and clinical characteristics
as shown in earlier studies [39].
We estimated the likelihood of cirrhosis advancing to DC from a
pooled analysis of ﬁve studies [17–21] and cirrhosis advancing to
HCC from a pooled analysis of nine studies [17–25]. The baseline
likelihood of developing HCC from DC and the annual mortality
associated with DC were estimated from a study by Planas et al. [26]
that followed 200 patients with DC for a mean period of 32 months.
The patients developing DC or HCC were eligible to receive an LT.
The mortality associated with LT was estimated from a recently
published study [31], which was not speciﬁc to patients with HCV;
however, this was tested by sensitivity analysis. The age- and sex-
speciﬁc all-cause mortality rates were taken from US life tables [40].
Probability of Receiving an LT
Most of the previously published US-based cost-effectiveness
models used the probability of receiving an LT from DC estimated
Table 2 – Treatment-related outcomes of patients enrolled in RESPOND-2.
Treatment characteristics PR48 (n ¼ 80) BOC/RGT (n ¼ 162) BOC/PR48 (n ¼ 161)
Experienced anemia, n (%) 16 (20)* 70 (43) 75 (47)
EPO use, n (%) 17 (21) 66 (41) 74 (46)
Mean duration of anemia (d) 97.4 122.1 150.6
Mean duration of EPO use (d) 64.6 135.0 130.2
Discontinued before TW12, n/m (%) 5/80 (6) 13/162 (8) 4/161 (2.5)
Discontinued because of treatment failure at TW12, n/m (%)† 49/75 (65) 36/149 (24) 29/157 (18)
Discontinued after TW12, n/m (%)† 3/26 (12) 7/113 (6) 23/128 (18)
Assigned 36-wk therapy, n/m (%)† NA 66/106 (62) NA
Sustained virologic response (SVR), n (%) 17 (21) 95 (59) 107 (66)
BOC/PR48, peginterferon–ribavirin-boceprevir regimen; BOC/RGT, response-guided therapy; EPO, erythropoietin; NA, not applicable; PR48,
peginterferon-ribavirin regimen; RESPOND-2, Serine Protease Inhibitor Boceprevir and PegIntron/Rebetol-2; TW, therapy week.
* All patients receiving EPO were assumed as anemic by the model. Because more patients received EPO than who experienced anemia in PR48,
the number of patients who experienced anemia in PR48 was assumed to be 17 in the model.
† Conditional on the proportion of subjects reaching this week in the trial (as needed by the model). The denominator was determined by the
number of patients in the trial at the given week.
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prevalence of DC in the US population, however, have changed
since then. For example, according to the analysis of the Scien-
tiﬁc Registry of Liver Transplant Recipients data, from 1999 to
2007, the number of recipients with HCV increased to a peak of
2,481 in 2006 and remained relatively unchanged afterwards [27].
Also, HCV-related DC became more prevalent after 1995 [28]. By
using the approach of Bennett et al. [14] and most recent data, we
estimated the annual probability of a patient with DC receiving
an LT to be equal to 2.33% (i.e., 2,400/103,117). Our estimate is
lower than that of Bennett et al. (3.1%) primarily because of a
substantial increase in the prevalence of DC since then. Finally,
we estimated the annual probability of a patient with HCC
receiving an LT to be 4.0% from a study by Lang et al. [29].
Treatment Costs
The model was developed from the payer perspective. We esti-
mated the baseline health-state–speciﬁc annual costs from a study
by McAdam-Marx et al. [34] that conducted a retrospective,
matched cohort study of 34,597 patients with HCV enrolled in a
large managed care claims database. We subtracted pharmacy-
related costs from HCV states without cirrhosis (F0–F3) and
compensated cirrhosis (F4), which were primarily due to antiviral
therapy. We also adjusted the inpatient hospitalization costs by
using the national hospital cost-to-charge ratio of 0.329, which
was estimated by taking the weighted average of statewide
operating cost-to-charge ratio [41] and the number of hospital
discharges in each state [42]. McAdam-Marx et al. provided only
the combined cost associated with health states F0 to F3. To
estimate the cost associated with each ﬁbrosis stage, we used the
proportion of cost spent in each health state—mild (F0, F1) to
moderate (F2) to severe (F3) chronic HCV—from another study [35].
The total treatment costs for patients on antiviral therapy
were based on the weekly drug costs and monitoring costs. We
assumed the drug costs to be equal to the wholesale acquisition
cost as listed by First DataBank [32]. The price of pegylated
interferon alfa-2b was $587.51 per week. By using the price of
the generic version of ribavirin equal to $8.83 per 200 mg capsule
at a daily dose of 1000 mg and the mean patient body weight of
approximately 80 kg, we estimated the weekly cost of ribavirin at
$309.05. The weekly cost of boceprevir was $1100. The cost of
treating anemia was estimated by using the percentage of
patients who used EPO (at a weekly cost of $875) and the mean
duration of EPO in the trial. We added a weekly monitoring cost
of $64, which included physician visits, blood cell counts, liver
function tests, and HCV quantitative polymerase chain reactiontests. We did not include any indirect costs (e.g., lost productivity)
in the model. An annual discount rate of 3% was applied to future
costs accrued.
Utility weights
All treatment and health-state–speciﬁc utility weights were esti-
mated from a previously published study using the EuroQol ﬁve-
dimensional questionnaire instrument [12,38], and adjusted to the
US population norm [36]. Quality of life (QOL) of patients who
achieved SVR was assumed to be equivalent to that of the general
population [38]. Future QALYs were discounted at 3% per year.
Outcomes
Our model provided the average total costs and QALYs associated
with each treatment strategy, and the incremental cost-effectiveness
ratios (ICERs) per additional QALY of boceprevir-based regimens
—BOC/PR48 and BOC/RGT—compared incrementally with PR.
In addition, we projected the incidence of advanced liver-
related complications (DC and HCC), LTs, and liver-related deaths
(LRDs) with the three treatment strategies. A half-cycle correction
was performed when calculating all outcomes. Finally, we per-
formed one-way and probabilistic sensitivity analysis (PSA) to
measure uncertainty in outcomes because of uncertainty in the
efﬁcacy, epidemiology, QOL, discount rates, and cost inputs.Results
We cross-validated our model by comparing the natural history
of HCV infection with previously published models. For this
purpose, we projected the 20-year cumulative probability of
developing cirrhosis in a 44-year-old untreated patient with F0
and F1 stage equal to 17.2% and 35.5%, respectively. Siebert et al.
[12] projected the 20-year probability of cirrhosis in a 44-year-old
patient with mild chronic HCV to be equal to 27%, and Bennett
et al. [14] projected the corresponding probability in a 35-year-old
patient with mild chronic HCV to be equal to 28%. Assuming 35%
of the patients with mild HCV with the F0 stage and 65% with the
F1 stage in 2010 [28], our model predicted the 20-year cirrhosis
probability of 29.1% in a 44-year old patient, which is comparable
to reported values. Salomon et al. [11] projected 30-year cumu-
lative probability from F0 to cirrhosis and F2 to cirrhosis equal to
20% and 65%, respectively. The corresponding probabilities from
our model were higher at 38.2% and 79%, respectively.
We also compared our results with a recently published
multicenter follow-up study of patients with advanced ﬁbrosis
Table 3 – Clinical, cost, and quality-of-life inputs, and SVR rates: baseline values, ranges, and parameters for
distributions used in deterministic and probabilistic sensitivity analyses.
Input Base
case
Range Distribution Parameter
1*
Parameter
2†
Transition probabilities (annual)
F0–F1 [16] 0.117 0.104–0.130 Beta 274.98 2,075.30
F1–F2 [16] 0.085 0.075–0.096 Beta 210.06 2,261.18
F2–F3 [16] 0.120 0.109–0.133 Beta 288.05 2,112.38
F3–F4 [16] 0.116 0.104–0.129 Beta 270.61 2,062.22
Cirrhosis to DC [17–21] 0.029 0.010–0.039 Beta 16.67 558.01
Cirrhosis to HCC [17–25] 0.028 0.010–0.079 Beta 22.97 791.67
SVR after cirrhosis to DC [15] 0.008 0.002–0.036 Beta 6,348.80 787,251.20
SVR after cirrhosis to HCC [15] 0.005 0.002–0.013 Beta 2,487.50 495,012.50
DC to HCC [26] 0.068 0.030–0.083 Beta 10.88 149.15
DC to transplantation [27,28] 0.023 0.010–0.062 Beta 1.31 55.44
DC (ﬁrst year) to death from liver disease [26] 0.182 0.065–0.190 Beta 68.42 307.52
DC (subsequent year) to death from liver disease [26] 0.112 0.065–0.190 Beta 28.13 223.02
HCC to transplantation [29,30] 0.040 0.000–0.140 Beta 3.88 93.09
HCC to death from liver disease [18] 0.427 0.330–0.860 Beta 263.82 354.02
Liver transplantation (ﬁrst year) to death from liver
disease [31]
0.116 0.060–0.420 Beta 30.04 228.91
Following liver transplantation to death from liver
disease [31]
0.044 0.024–0.110 Beta 4.67 101.55
Drug therapy–related costs (weekly)
Peginterferon alfa-2b [32] 588
Ribavirin [32] 309
Boceprevir [32] 1,100
Erythropoietin (40,000 IU/mL) [32] 875
Monitoring costs [33] 64
Health state costs (annual)
F0, F1 [34,35] 678 25% Gamma 61.47 11.03
F2 [34,35] 687 25% Gamma 61.47 11.17
F3 [34,35] 1,394 25% Gamma 61.47 22.67
Compensated cirrhosis [34] 1,626 25% Gamma 61.47 26.46
DC [34] 18,064 25% Gamma 61.47 293.89
HCC [34] 33,218 25% Gamma 61.47 540.44
Liver transplant (ﬁrst year) [34] 95,971 25% Gamma 61.47 1,561.38
Following liver transplant [34] 25,208 25% Gamma 61.47 410.11
Health state quality-of-life weights
US population norms, men [36]
20–29 y 0.928 0.922–0.934 Beta 6,616.65 513.36
30–39 y 0.918 0.912–0.925 Beta 7,374.10 658.69
40–49 y 0.887 0.880–0.894 Beta 6,970.14 887.97
50–59 y 0.861 0.853–0.870 Beta 6,185.19 998.54
60–69 y 0.840 0.827–0.852 Beta 2,566.28 488.82
70–79 y 0.802 0.788–0.816 Beta 2,496.15 616.26
80–89 y 0.782 0.757–0.807 Beta 819.41 228.43
US population norms, women [36]
20–29 y 0.913 0.905–0.920 Beta 4,353.04 414.80
30–39 y 0.893 0.886–0.900 Beta 6,689.64 801.56
40–49 y 0.863 0.855–0.871 Beta 6,124.55 972.26
50–59 y 0.837 0.829–0.846 Beta 6,854.42 1,334.85
60–69 y 0.811 0.800–0.822 Beta 3,946.67 919.75
70–79 y 0.771 0.758–0.784 Beta 3,094.35 919.07
80–89 y 0.724 0.701–0.747 Beta 1,050.61 400.51
Drug therapy–related multiplier [12] 0.90 0.84–0.96 Beta 86.44 9.60
Anemia multiplier [37] 0.83 0.75–0.97 Beta 70.30 14.40
F0, F1 [38] 0.93 0.84–1.00 Beta 47.47 3.57
F2, F3 [38] 0.93 0.84–1.00 Beta 47.47 3.57
Compensated cirrhosis [38] 0.90 0.81–1.00 Beta 31.12 3.46
DC [38] 0.80 0.57–1.00 Beta 12.29 3.07
HCC [38] 0.79 0.54–1.00 Beta 11.42 3.03
First-year, following liver transplant [38] 0.84 0.77–0.93 Beta 53.54 10.20
Post-SVR 1.00 0.92–1.0 Beta 6,368.04 15.96
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Table 3 – continued
Input Base
case
Range Distribution Parameter
1*
Parameter
2†
SVR rates
PR48 [8] 0.21 0.13–0.30 Beta 19.56 72.50
BOC/RGT [8] 0.59 0.51–0.66 Beta 92.87 65.50
BOC/PR48 [8] 0.66 0.59–0.74 Beta 108.65 54.83
BOC/PR48, peginterferon–ribavirin-boceprevir regimen; BOC/RGT, response-guided therapy; DC, decompensated cirrhosis; HCC, hepatocellular
carcinoma; PR48, peginterferon-ribavirin regimen; SVR, sustained virologic response.
* Parameter 1 corresponds to the α parameter for beta distribution and the k (shape) parameter for gamma distribution.
† Parameter 2 corresponds to the β parameter for beta distribution and the θ (scale) parameter for gamma distribution.
V A L U E I N H E A L T H 1 6 ( 2 0 1 3 ) 9 7 3 – 9 8 6 979by van der Meer et al. [43]. In patients who failed to achieve SVR,
the study reported the 10-year cumulative incidence rates of DC,
HCC, and combined LRD and LT equal to 29.9% (CI 24.3%–35.5%),
21.8% (95% CI 16.6%–27.0%), and 27.4% (95% CI 22.0%–32.8%),
respectively. The corresponding values predicted by our model
were 17.0%, 18.7%, and 23.7%, respectively. The predicted inci-
dence of HCC and LRD plus LT in this group was within the
reported CIs; however, the incidence of DC was lower than the
reported values. In patients who achieved SVR, the study
reported the 10-year cumulative incidence rates of DC, HCC,
and combined LRD and LT equal to 2.1% (95% CI 0%–4.5%), 5.1%
(95% CI 1.3%–8.9%), and 1.9% (95% CI 0%–4.1%), respectively. The
corresponding values predicted by our model were 5.2%, 3.9%,
and 5.6%, respectively. The predicted incidence of HCC in this
group was within the reported CIs; however, the incidence of DC
and LRD plus LT was higher than the reported values.
Base-Case Analysis
Treatment with PR therapy would result in a 16.0% likelihood of
DC compared with 9.4% (relative reduction of 41.1%) with BOC/RGT
and 8.1% (relative reduction of 49.4%) with BOC/PR48 (Fig. 3).
Similarly, the likelihood of HCC, LT, and LRD was projected to
reduce by 41.1% to 52.0% with boceprevir-based regimens in
comparison with PR48. The total projected life-years associated
with PR48, BOC/RGT, and BOC/PR48 were 24.74, 26.07, and 26.34,
respectively, and the corresponding discounted QALYs were
12.79, 13.64, and 13.80, respectively (Table 4). The total expected
discounted lifetime costs of PR48, BOC/RGT, and BOC/PR48 were
$53,500, $79,000, and $94,500, respectively. The average bocepre-
vir cost account for 33% and 39% of total HCV-associated cost in
BOC/RGT and BOC/PR48, respectively (Table 4). The ICER of BOC/
RGT in comparison with that of PR48 was $30,200 per QALY, and
the ICER of BOC/PR48 in comparison with that of BOC/RGT was
$91,500 per QALY.
Sensitivity Analysis
We performed one-way sensitivity analysis on efﬁcacy, transition
probabilities, QOL weights, discount rates, and treatment-related
costs, and identiﬁed the top 25 variables that had the biggest
impact on ICERs by plotting the tornado diagrams (Figs. 4 and 5).
We found that ICERs were most sensitive to the SVR rates,
discount rate, probability of DC or HCC in patients with cirrhosis,
probability of DC after achieving SVR, and QOL weights associ-
ated with ﬁbrosis stages F0 to F4.
We also analyzed a scenario in which 24% of the patients with
the F0 stage will not progress even without treatment, and found
similar results as with the base-case analysis. Next, we per-
formed sensitivity analysis by including the hazard ratio for sex-,
race-, and age-speciﬁc mortality (white male: 2.56; white female:
1.90; black male: 2.75; and black female: 2.48) from nonlivercauses in patients with chronic HCV [13]. By using the proportion
of blacks and whites from RESPOND-2, we estimated the
weighted hazard ratio for males as 2.58 and females as 1.97. We
linearly decreased the hazard ratio from age 70 years onwards to
1.0 by age 100 years to avoid the overestimation of mortality in
older patients. The cost of PR48, BOC/RGT, and BOC/PR48 went
down to $50,000, $74,600, and $90,568 respectively. The corre-
sponding QALYs went down to 10.63, 11.22, and 11.34, respec-
tively. The ICER of BOC/RGT in comparison with that of PR48 was
$48,900 per QALY, and the ICER of BOC/PR48 in comparison with
that of BOC/RGT was $138,100 per QALY.
Next, we performed PSA on the parameters deﬁned in Table 3.
By using 10,000 Mote Carlo simulations, the total mean QALYs
associated with PR48, BOC/RGT, and BOC/PR48 were found to be
13.48, 14.48, and 14.61, respectively, and the corresponding total
expected cost was $55,785, $80,398, and $95,570, respectively. At a
willingness-to-pay (WTP) threshold of $50,000, the probabilities of
BOC/RGT and BOC/PR48 being the preferred option were 0.74 and
0.25, respectively (Fig. 6). At a WTP threshold of $100,000, the
corresponding probabilities were 0.41 and 0.59.
Subgroup Analysis: Prior Treatment Response
Efﬁcacy of re-treatment in patients who failed to achieve SVR
earlier depends on the patients’ response to prior treatment [8];
hence, the cost-effectiveness of re-treatment may vary by
patients’ prior treatment response. We performed cost-
effectiveness analysis in the following three subgroups: 1) Prior
relapsers, that is, patients with undetectable HCV-RNA levels at
the end of treatment but failed to achieve SVR; 2) Partial
responders, that is, patients whose HCV-RNA levels decreased
by at least 2 log10 at week 12 but remained detectable during the
therapy period); and 3) Null responders, that is, patients whose
HCV-RNA levels decreased by less than 2 log10 at week 12.
The treatment regimens and efﬁcacy data of prior relapsers
and partial responders were based on the RESPOND-2 study (see
Table S1 of the Appendix in Supplemental Materials found at
http://dx.doi.org/2010.1016/j.jval.2013.07.006). Because null res-
ponders were not included in RESPOND-2, we used data from
an ongoing PROVIDE study to evaluate the cost-effectiveness in
this subgroup [10]. For the comparator strategy of treatment with
peginterferon-ribavirin, we estimated model parameters of null
responders from an earlier study [44]. The treatment regimen of
null responders was deﬁned as follow: initiate with a lead-in
period with PR alone for 4 weeks, followed by BOC þ PR for 44
weeks (see Fig. S2 in Supplemental Materials found at http://dx.
doi.org/2010.1016/j.jval.2013.07.006). In all patients, the treatment
was stopped if they either had HCV-RNA greater than or equal to
100 IU/mL at treatment week 12, or detectable at treatment week
24. Table S2 in Supplemental Materials found at http://dx.doi.org/
2010.1016/j.jval.2013.07.006 summarizes treatment-related data
of null responders used in our model.
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Fig. 3 – Cumulative incidence of liver-related complications with PR48, BOC/RGT, and BOC/PR48 treatment strategies. BOC/
PR48, peginterferon–ribavirin-boceprevir regimen; BOC/RGT, response-guided therapy; DC, decompensated cirrhosis; HCC,
hepatocellular carcinoma; LT, liver transplant; PR48, peginterferon-ribavirin regimen. Error bars were estimated by using
10,000 Monte Carlo simulation runs.
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PR48 was $29,000, and the ICER of BOC/PR48 compared with BOC/
RGT was $134,300 (Table 5). In partial responders, the correspond-
ing ICERs were $33,600 and $58,200 per additional QALY. Finally,
in null responders, the ICER of boceprevir-based regimen in
comparison with PR48 was $33,300 per additional QALY. The
cost-effectiveness results in the three subgroups were compara-
ble, and the boceprevir-based triple therapy was cost-effective
(using a WTP threshold of $100,000) irrespective of prior treat-
ment response to therapy. Because RESPOND-2 was neither
designed nor powered to detect differences in outcomes by
treatment history, caution should be taken in interpreting the
cost-effectiveness of boceprevir in these subgroups.
Subgroup Analysis: IL-28B Genotype
Response to interferon-based therapies is known to depend on
interleukin (IL)-28B polymorphism [45]. Data from the RESPOND-2
study showed that single nucleotide polymorphism at IL-28B
rs12979860 is strongly associated with response to triple therapyTable 4 – Life expectancy, breakdown of total discounted
with each treatment strategy.
Category Cost ($)
PR48 BOC/RGT BOC
Life expectancy NA NA
Drug† 19,948 52,787 69
Anemia 1,716 6,875 7
Monitoring 1,423 1,929 2
SVR 0 0
F0–F3 7954 4560 3
F4 5,376 2,928 2
DC 5,933 3,560 3
HCC 7,096 4,070 3
Liver transplant 4,028 2,376 2
Total 53,474 79,085 94
ICER ($/QALY)
BOC/PR48, peginterferon–ribavirin-boceprevir regimen; BOC/RGT, respons
carcinoma; ICER, incremental cost-effectiveness ratio; PR48, peginterfero
* QALYs were rounded to two decimal places for reporting in the table,
† Drug cost includes dual-therapy cost for PR48 and triple-therapy cost f[46], with the CC genotype having a more favorable treatment
response than non-CC genotypes. Therefore, we evaluated the
cost-effectiveness of triple therapy by patient’s IL-28B genotype.
We used efﬁcacy as the main input of our subgroup analysis by
IL-28B genotypes. It should be noted that the RESPOND-2 trial
was neither designed nor powered to assess the impact of the IL-
28B genotype on the SVR. Also, approximately one third of the
patients in RESPOND-2 did not consent to genomic testing. For
these reasons, we did not include race (and other treatment-
speciﬁc parameters) into our analysis by the IL-28B genotype.
Because of the relatively low cost, we also did not include the cost
of a one-time genotype IL-28B test. Table S3 in Supplemental
Materials found at http://dx.doi.org/2010.1016/j.jval.2013.07.006
summarizes the data available from RESPOND-2 that was used
in our model. Because discontinuation rates and treatment
failure rates were not available by the IL-28B genotype, we used
the corresponding rates as estimated in base-case analysis.
In IL-28B CC patients, the ICER of BOC/RGT in comparison
with PR48 was $35,400 per additional quality-adjusted life-yearexpected costs and QALYs, and the ICER associated
QALYs*
/PR48 PR48 BOC/RGT BOC/PR48
NA 24.74 26.07 26.34
,776 NA NA NA
,480 –0.01 –0.02 –0.02
,376 NA NA NA
0 2.90 7.99 9.06
843 7.06 4.1 3.47
,428 2.41 1.31 1.09
,078 0.21 0.13 0.11
,453 0.14 0.08 0.07
,041 0.08 0.05 0.04
,475 12.79 13.64 13.8
– 30,241 91,506
e-guided therapy; DC, decompensated cirrhosis; HCC, hepatocellular
n-ribavirin regimen; QALYs, quality-adjusted life-years.
but ICERs were estimated by using exact QALYs from the model.
or BOC/RGT and BOC/PR48.
Fig. 4 – Tornado diagram showing 25 most sensitive parameters in BOC/RGT. BOC/RGT, response-guided therapy; c, cost; DC,
decompensated cirrhosis; HCC, hepatocellular carcinoma; ICER, incremental cost-effectiveness ratio; p, transition probability;
PR48, peginterferon-ribavirin regimen; q, quality-of-life weight; SVR, sustained virologic response.
V A L U E I N H E A L T H 1 6 ( 2 0 1 3 ) 9 7 3 – 9 8 6 981(QALY), and BOC/PR48 was dominated (Table 5). In IL-28B CT
patients, the ICERs of BOC/RGT and BOC/PR48 were $24,800 and
$51,400 per additional QALY, respectively. Finally, in IL-28B TT
patients, BOC/RGT was ruled out using extended or weak dom-
inance principle (because BOC/RGT had lower QALYs but higher
ICER than did BOC/PR48), resulting in BOC/PR48’s ICER of $97,000
per additional QALY in comparison with PR48. By using a WTP
threshold of $100,000, boceprevir-based RGT was found to be
cost-effective in patients with genotype CC and genotype CT.
BOC/RGT, however, was weakly dominated in patients with
genotype TT; instead, the 48-week ﬁxed-treatment arm was
cost-effective in patients with genotype TT. RESPOND-2 was
neither designed nor powered to detect differences in outcomes
by the IL-28B genotype; therefore, caution should be taken in
interpreting the cost-effectiveness of boceprevir in these
subgroups.
Scenario Analysis: Food and Drug Administration–Approved
Regimens
The Food and Drug Administration (FDA) recommendations and
the American Association for the Study of Liver Diseases treat-
ment guidelines for the use of boceprevir are different than those
studied in RESPOND-2; therefore, our model also simulated the
recommended treatment design [47]. The FDA recommends BOC/
RGT in treatment-experienced patients without cirrhosis who are
prior relapsers or partial responders, and ﬁxed-duration therapy
of 48 weeks in null responders and patients with cirrhosis (see
Figs. S1 and S2 in Supplemental Materials found at http://dx.doi.org/2010.1016/j.jval.2013.07.006). In addition, the boceprevir label
recommended a different stopping rule than that applied in the
RESPOND-2 trial. We performed post hoc analysis to estimate
label-related model parameters (details are provided in Table S4
in Supplemental Materials found at http://dx.doi.org/2010.1016/j.
jval.2013.07.006).
In patients without cirrhosis, the ICER of PR þ BOC in compar-
ison with that of PR was $35,300/QALY (Table 5). In patients with
cirrhosis, the ICER of PR þ BOC in comparison with that of PR was
$10,100 per additional QALY. In comparison with the trial-based
analysis, the label-based analysis shows a more favorable cost-
effectiveness of treatment with triple therapy. In addition, the
treatment with triple therapy provides more beneﬁts per dollar
spent in patients with cirrhosis than in patients without cirrhosis.Scenario Analysis: Management of Anemia with Ribavirin
Dose Reduction
Although EPO was used to manage anemia in RESPOND-2, a
recent study showed that SVR rates in patients managed with
ribavirin dose reduction alone were comparable to those in
patients managed with EPO [48]. Our base-case analysis assumed
management of anemia with EPO use as observed in the trial;
however, we also analyzed a scenario in which all anemic
patients would be managed with ribavirin dose reduction only.
For this scenario, the ICER of BOC/RGT in comparison with that of
PR48 and the ICER of BOC/PR48 in comparison with that of BOC/
RGT went down to $24,100 and $87,900, respectively (Table 5).
Fig. 5 – Tornado diagram showing 25 most sensitive parameters in BOC/PR48. BOC/PR48, peginterferon–ribavirin-boceprevir
regimen; BOC/RGT, response-guided therapy; c, cost; DC, decompensated cirrhosis; HCC, hepatocellular carcinoma; ICER,
incremental cost-effectiveness ratio; p, transition probability; q, quality-of-life weight; SVR, sustained virologic response.
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In addition to boceprevir, FDA approved another protease inhi-
bitor, telaprevir, for chronic hepatitis C treatment in previously
treated patients [7]. Because no head-to-head trial compares
the effectiveness of telaprevir with boceprevir, and the base-
line patient characteristics, adverse event proﬁles, and futilityFig. 6 – Cost-effectiveness acceptability curve. BOC/PR48, pegint
guided therapy; PR48, peginterferon-ribavirin regimen.rules of RESPOND-2 and REALIZE were different, direct
comparison of the cost-effectiveness of the two drugs was
not feasible. Therefore, we evaluated only the cost-effective-
ness of telaprevir in previously treated patients in comparison
with peginterferon-ribavirin using data from the REALIZE
study [7].erferon–ribavirin-boceprevir regimen; BOC/RGT, response-
Table 5 – Subgroup and scenario analysis of total discounted expected costs and QALYs, and the ICER
associated with each treatment strategy.
Treatment strategy
Cost ($)
QALYs
ICER ($/QALY)
Prob. of CE at $50K
Prob. of CE at $100K
Subgroup analysis by prior treatment response
Prior relapser
PR48 54,413 12.98 – 0.022 0
BOC/RGT 80,208 13.87 29,017 0.830 0.556
BOC/PR48 97,225 13.99 134,363 0.148 0.444
Partial responder
PR48 51,897 12.46 – 0.062 0
BOC/RGT 77,716 13.23 33,613 0.510 0.313
BOC/PR48 91,846 13.47 58.177 0.428 0.687
Null responder
PR48 51,149 12.30 – 0.059 0.001
BOC/PR48 80,487 13.18 33,255 0.941 0.999
Subgroup analysis by IL-28B rs12979860 genotype
IL-28B genotype CC
PR48 45,225 13.35 – 0.259 0.080
BOC/RGT 71,372 14.08 35,444 0.672 0.717
BOC/PR48 90,893 14.05 Dominated* 0.069 0.203
IL-28B genotype CT
PR48 54,803 12.70 – 0.005 0
BOC/RGT 79,468 13.69 24,832 0.539 0.291
BOC/PR48 92,399 13.94 51,393 0.456 0.709
IL-28B genotype TT
PR48 43,951 13.43 0.680 0.401
BOC/RGT 82,746 13.54 Dominated† 0.138 0.152
BOC/PR48 92,566 13.93 97,077 0.182 0.447
Scenario analysis: FDA-approved regimens
All previously treated
PR48-FDA 55,603 12.73 – 0 0
BOC/PR-FDA 84,011 13.83 25,747 1 1
Patients without cirrhosis (Metavir F0–F3)
PR48-FDA 51,125 13.26 – 0.065 0
BOC/PR-FDA 78,947 14.05 35,285 0.935 1
Patients with cirrhosis (Metavir F4)
PR48-FDA 85,394 9.18 – 0 0
BOC/PR-FDA 117,701 12.37 10,102 1 1
Scenario analysis: management of anemia with ribavirin dose reduction
PR48 51,759 12.79 – 0.001 0
BOC/RGT 72,209 13.64 24,149 0.729 0.406
BOC/PR48 86,995 13.80 87,906 0.270 0.594
Scenario analysis: telaprevir vs. peginterferon-ribavirin
All previously treated
REALIZE-PR48 71,299 12.32 – 0 0
TEL12PR48 108,795 13.85 24,431 1 1
Prior relapser
REALIZE-PR48 76,040 12.55 – 0 0
TEL12PR48 103,595 14.47 14,397 1 1
Partial responder
REALIZE-PR48 63,417 12.23 – 0 0.001
TEL12PR48 107,135 13.67 30,322 1 0.999
Null responder
REALIZE-PR48 67,516 11.94 – 0.942 0
TEL12PR48 120,214 12.73 66,779 0.058 1
BOC/PR48 peginterferon–ribavirin-boceprevir regimen as in the RESPOND-2 trial; BOC/PR-FDA, boceprevir-based triple therapy as in the FDA-
approved label; BOC/RGT, response-guided therapy as in the RESPOND-2 trial; CE, cost-effectiveness; FDA, Food and Drug Administration;
ICER, incremental cost-effectiveness ratio; Prob., probability, PR48, peginterferon-ribavirin regimen as in the RESPOND-2 trial; PR48-FDA,
peginterferon-ribavirin regimen as in the FDA-approved label; QALY, quality-adjusted life-year; REALIZE, retreatment of patients with
telaprevir-based regimen to optimize outcomes; REALIZE-PR48, peginterferon-ribavirin regimen as in the REALIZE trial; RESPOND-2, Serine
Protease Inhibitor Boceprevir and PegIntron/Rebetol-2; TEL12PR48, telaprevir-based triple therapy as in the REALIZE trial.
* BOC/PR48 was dominated because it had lower QALYs but higher cost than did BOC/RGT.
† BOC/RGT was weakly dominated because it had lower QALYs but higher ICER than did BOC/PR48.
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parts: the ﬁrst part simulated the treatment strategies, and the
second part modeled the natural history of the hepatitis C
disease. We simulated treatment with peginterferon plus riba-
virin for 48 weeks (REALIZE-PR48) and the FDA-approved treat-
ment arm using telaprevir for 12 weeks and peginterferon plus
ribavirin for a total of 48 weeks without any lead-in (T12PR48).
The treatment was discontinued if patients had less than a 2
log10 decrease in HCV-RNA levels at week 12 (futility rule). All
treatment-related parameters are summarized in Table S5 of the
Appendix in Supplemental Materials found at http://dx.doi.org/
2010.1016/j.jval.2013.07.006. Any patient who either failed to
achieve SVR or a patient with cirrhosis (even if he or she achieved
SVR) continued to the natural history part of the model.
By using the telaprevir price of $4,400 per week, the ICER of
T12PR48 in comparison with that of REALIZE-PR48 was found to
be $24,400/QALY (Table 5). The cost-effectiveness of telaprevir
compared with that of PR was more favorable in prior relapsers
(ICER ¼ $14,400/QALY) and partial responders (ICER ¼ $30,300/
QALY) than in null responders (ICER ¼ $66,800/QALY).Discussion
A signiﬁcant increase in SVR rates was observed in patients
treated with boceprevir-based therapies over PR therapy alone in
RESPOND-2 and PROVIDE [8]. It is not clear, however, whether the
boceprevir-containing regimens provide sufﬁcient value in pre-
viously treated patients given the high cost of triple therapy. We
developed a Markov-cohort model to project the lifetime clinical
burden of HCV, total cost, and cost-effectiveness of boceprevir-
based regimens studied in RESPOND-2 and PROVIDE. We also
estimated the cost-effectiveness of boceprevir regimens as per
FDA recommendations and American Association for the Study
of Liver Diseases guidelines, and telaprevir-based regimens as
studied in the REALIZE trial.
Boceprevir-based regimens were projected to reduce the
incidence of liver-related complications (DC and HCC), mortality,
and LTs by 43% to 53% in comparison with treatment with PR
alone. At a price of $1,100 per week, only RGT was cost-effective
at a WTP threshold of $50,000/QALY , whereas both RGT and
ﬁxed-duration therapy for 48 weeks were cost-effective at a WTP
threshold of $100,000/QALY . In addition, boceprevir-based regi-
mens as approved by the FDA were also cost-effective in pre-
viously treated patients with HCV genotype 1 but with and
without cirrhosis.
We performed subgroup analysis by prior treatment response
and patient’s IL-28B genotype. Our results show that both
boceprevir-based therapies were cost-effective irrespective of
patient’s prior response to treatment, that is, prior relapsers,
partial responders, and null responders. Second, the boceprevir-
based RGT was found to be cost-effective in patients with the IL-
28B genotype CC and CT at a WTP threshold of $50,000, whereas
in patients with the IL-28B genotype TT, boceprevir-based RGT
therapy was weakly dominated by ﬁxed-duration boceprevir-
based therapy, which was cost-effective only at a WTP threshold
of $100,000. Because RESPOND-2 was neither powered nor
designed to detect differences by subgroups, caution should be
taken in interpreting the cost-effectiveness results in these
subgroups.
We also evaluated the cost-effectiveness of telaprevir-based
triple therapy in comparison with that of peginterferon-ribavirin
using REALIZE trial results. At a price of $4,400 per week,
telaprevir-based therapy was cost-effective in patients with
genotype 1 who are prior relapsers and partial responders (using
the WTP threshold of $50,000). In null responders, however,
telaprevir-based therapy was cost-effective only at the WTPthreshold of $100,000. We did not perform a direct comparison
of cost-effectiveness of telaprevir with boceprevir because no
head-to-head trial compares the effectiveness of these two drugs.
Our model was extensively validated against a recently
published clinical study as well as with other modeling studies.
The predicted progression to advanced HCV diseases in patients
who failed to achieve SVR was lower and in patients who
achieved SVR was higher in comparison to those reported in
van der Meer et al. [43]. This trend may have resulted in an
overestimation of ICERs of boceprevir-based regimens. In com-
parison with the modeling study of Salomon et al. [11], our model
projected faster progression of ﬁbrosis in untreated patients. The
difference could be attributed to the exclusion of nonprogressing
patients in stage F0, different natural history parameters, and
assumption of no higher all-cause mortality in the base model.
However, our model’s ﬁbrosis progression rates were similar to
those reported in Bennett et al. [14] and Siebert et al. [12].
A recently published study evaluated the cost-effectiveness of
boceprevir and telaprevir in patients who failed prior treatment
in Europe and found very similar results [49]. To our knowledge,
no previous study has evaluated the cost-effectiveness of treat-
ment with PIs in patients who failed prior treatment in the
United States. Several studies have evaluated the cost-
effectiveness of PIs in treatment-naive patients [13,50,51]. We
also made several updates in the model structure and inputs, in
comparison with previously published models on hepatitis C.
First, our model included two components—treatment phase and
natural history phase—and included early discontinuations and
management of anemia. Second, we estimated the probability of
receiving an LT that takes into account the changes in the
practice over the last two decades. Third, we estimated the
probability of HCC after cirrhosis or DC by using a pooled analysis
of several studies. Fourth, unlike most previous models, we
allowed for a progression of disease in patients with cirrhosis
even after they attained SVR. Finally, we estimated health-state–
related costs by using a recent data and appropriate cohort of
patients with hepatitis C.
Sensitivity analysis showed that the ICERs were most sensi-
tive to the joint discount rates for costs and QALYs. We also
found that ICERs were sensitive to the probability of development
of HCC or DC in patients with cirrhosis, and QOL weights
associated with ﬁbrosis stages. This underscores a need for a
better understanding of the natural history of end-stage liver
diseases and QOL of patients with HCV. When we considered a
higher mortality due to nonliver causes in patients with HCV,
only RGT was cost-effective in comparison with PR-based therapy
at a WTP threshold of $100,000. Finally, PSA showed that
boceprevir-based regimens were cost-effective with a very high
probability at commonly used WTP thresholds. In general, our
conclusions were robust to a wide range of input parameters.
Our study has several limitations. First, we did not model the
possibility of reinfection after a patient in stage F3 achieved SVR
and assumed that DC and HCC are mutually exclusive, whereas
this may not be the case in real life. This may have under-
estimated the ICERs of boceprevir-based therapies. Second, our
model cannot be applied to special populations such as HIV-HCV
or HBV-HCV coinfected patients because RESPOND-2 enrolled
patients without such coinfections. Third, we assumed that there
is no progression of disease while patients are on treatment,
which may have some impact (albeit small) on our results.
Fourth, our model was based on trial data whereas treatment-
related parameters such as SVR rates, discontinuations, and
treatment-completion rates may be different in practice, and
inﬂuence the cost-effectiveness of boceprevir-based regimens.
Fifth, we did not use higher all-cause mortality in patients with
HCV in our base case, which resulted in an underestimation of
ICERs of boceprevir-based therapies. Sixth, our PSA assumed
V A L U E I N H E A L T H 1 6 ( 2 0 1 3 ) 9 7 3 – 9 8 6 985independence of all variables; however, costs and QOL weights
are correlated, which may potentially bias our results. Finally,
though IL-28B-guided therapy may be valuable in treatment-
experienced patients, considering the above factors and lack of
reliable data on IL-28B in treatment-experienced patients, we did
not perform IL-28B genotype–guided analysis.
In summary, PIs were projected to substantially reduce the
burden of liver-related complications such as DC, HCC, liver-
related mortality, and LTs in previously treated patients with
HCV genotype 1. In addition, ﬁrst-generation PIs were projected
to be cost-effective in comparison with treatment with peginter-
feron and ribavirin in previously treated patients at a WTP
threshold of $100,000 [44].Acknowledgments
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